Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1995 Jul;69(7):4267–4273. doi: 10.1128/jvi.69.7.4267-4273.1995

Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies.

L Burkly 1, N Mulrey 1, R Blumenthal 1, D S Dimitrov 1
PMCID: PMC189165  PMID: 7769687

Abstract

Antibodies to several epitopes of the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (gp120-gp41) can synergize in inhibiting HIV-1 infection. In the present study we tested the ability of a monoclonal antibody (MAb), 5A8, which interacts with CD4 domain 2, and other CD4-specific MAbs to synergize with antibodies against gp120. We have previously found that 5A8 inhibits HIV-1 entry without interfering with gp120 binding to CD4, presumably by affecting a postbinding membrane fusion event. Because antibodies to the gp120 V3 loop also affect post-CD4-gp120-binding events, 5A8 was first tested in combination with anti-V3 loop antibodies for possible synergy. The anti-V3 loop antibodies 0.5 beta, NEA-9205, and 110.5 acted synergistically with 5A8 in inhibiting syncytium formation between gp120-gp41- and CD4-expressing cells. A human MAb to an epitope of gp120 involved in CD4 binding, IAM 120-1B1, and another anti-CD4 binding site antibody, PC39.13, also exerted synergistic effects in combination with 5A8. Similarly, an antibody against the gp120 binding site on CD4, 6H10, acted synergistically with an anti-V3 loop antibody, NEA-9205. However, a control anti-CD4 antibody, OKT4, which does not significantly inhibit syncytium formation alone, produced only an additive effect when combined with NEA-9205. Serum from HIV-1-infected individuals, which presumably contains antibodies to the V3 loop and the CD4 binding site, exhibited a strong synergistic effect with 5A8 in inhibiting infection by a patient HIV-1 isolate (0104B) and in blocking syncytium formation. These results indicate that therapeutics based on antibodies affecting both non-gp120 binding and gp120 binding epitopes of the target receptor molecule, CD4, could be efficient in patients who already contain anti-gp120 antibodies and could also be used to enhance passive immunization against HIV-1 in combination with anti-gp120 antibodies.

Full Text

The Full Text of this article is available as a PDF (222.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berenbaum M. C. The expected effect of a combination of agents: the general solution. J Theor Biol. 1985 Jun 7;114(3):413–431. doi: 10.1016/s0022-5193(85)80176-4. [DOI] [PubMed] [Google Scholar]
  2. Buchbinder A., Karwowska S., Gorny M. K., Burda S. T., Zolla-Pazner S. Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains. AIDS Res Hum Retroviruses. 1992 Apr;8(4):425–427. doi: 10.1089/aid.1992.8.425. [DOI] [PubMed] [Google Scholar]
  3. Burkly L. C., Olson D., Shapiro R., Winkler G., Rosa J. J., Thomas D. W., Williams C., Chisholm P. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol. 1992 Sep 1;149(5):1779–1787. [PubMed] [Google Scholar]
  4. Cassatt D. R., Sweet R. W., Arthos J. A., Truneh A. Immunization with soluble murine CD4 induces an anti-self antibody response without causing impairment of immune function. J Immunol. 1991 Sep 1;147(5):1470–1476. [PubMed] [Google Scholar]
  5. Cavacini L. A., Emes C. L., Power J., Buchbinder A., Zolla-Pazner S., Posner M. R. Human monoclonal antibodies to the V3 loop of HIV-1 gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site. J Acquir Immune Defic Syndr. 1993 Apr;6(4):353–358. [PubMed] [Google Scholar]
  6. Chou T. C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55. doi: 10.1016/0065-2571(84)90007-4. [DOI] [PubMed] [Google Scholar]
  7. Dalgleish A. G., Beverley P. C., Clapham P. R., Crawford D. H., Greaves M. F., Weiss R. A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984 Dec 20;312(5996):763–767. doi: 10.1038/312763a0. [DOI] [PubMed] [Google Scholar]
  8. Dhiver C., Olive D., Rousseau S., Tamalet C., Lopez M., Galindo J. R., Mourens M., Hirn M., Gastaut J. A., Mawas C. Pilot phase I study using zidovudine in association with a 10-day course of anti-CD4 monoclonal antibody in seven AIDS patients. AIDS. 1989 Dec;3(12):835–842. doi: 10.1097/00002030-198912000-00009. [DOI] [PubMed] [Google Scholar]
  9. Dimitrov D. S., Blumenthal R. Photoinactivation and kinetics of membrane fusion mediated by the human immunodeficiency virus type 1 envelope glycoprotein. J Virol. 1994 Mar;68(3):1956–1961. doi: 10.1128/jvi.68.3.1956-1961.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Earl P. L., Koenig S., Moss B. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses. J Virol. 1991 Jan;65(1):31–41. doi: 10.1128/jvi.65.1.31-41.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Elson H. F., Dimitrov D. S., Blumenthal R. A trans-dominant mutation in human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp41 inhibits membrane fusion when expressed in target cells. Mol Membr Biol. 1994 Jul-Sep;11(3):165–169. doi: 10.3109/09687689409162235. [DOI] [PubMed] [Google Scholar]
  12. Freed E. O., Delwart E. L., Buchschacher G. L., Jr, Panganiban A. T. A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):70–74. doi: 10.1073/pnas.89.1.70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hillman K., Shapira-Nahor O., Gruber M. F., Hooley J., Manischewitz J., Seeman R., Vujcic L., Geyer S. J., Golding H. Chemically induced CD4 mutants of a human T cell line. Evidence for dissociation between binding of HIV I envelope and susceptibility to HIV I infection and syncytia formation. J Immunol. 1990 Mar 15;144(6):2131–2139. [PubMed] [Google Scholar]
  14. Jonker M., Neuhaus P., Zurcher C., Fucello A., Goldstein G. OKT4 and OKT4A antibody treatment as immunosuppression for kidney transplantation in rhesus monkeys. Transplantation. 1985 Mar;39(3):247–253. doi: 10.1097/00007890-198503000-00006. [DOI] [PubMed] [Google Scholar]
  15. Kennedy M. S., Orloff S., Ibegbu C. C., Odell C. D., Maddon P. J., McDougal J. S. Analysis of synergism/antagonism between HIV-1 antibody-positive human sera and soluble CD4 in blocking HIV-1 binding and infectivity. AIDS Res Hum Retroviruses. 1991 Dec;7(12):975–981. doi: 10.1089/aid.1991.7.975. [DOI] [PubMed] [Google Scholar]
  16. Klatzmann D., Champagne E., Chamaret S., Gruest J., Guetard D., Hercend T., Gluckman J. C., Montagnier L. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature. 1984 Dec 20;312(5996):767–768. doi: 10.1038/312767a0. [DOI] [PubMed] [Google Scholar]
  17. Laal S., Burda S., Gorny M. K., Karwowska S., Buchbinder A., Zolla-Pazner S. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J Virol. 1994 Jun;68(6):4001–4008. doi: 10.1128/jvi.68.6.4001-4008.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lifson J. D., Reyes G. R., McGrath M. S., Stein B. S., Engleman E. G. AIDS retrovirus induced cytopathology: giant cell formation and involvement of CD4 antigen. Science. 1986 May 30;232(4754):1123–1127. doi: 10.1126/science.3010463. [DOI] [PubMed] [Google Scholar]
  19. McDougal J. S., Kennedy M. S., Sligh J. M., Cort S. P., Mawle A., Nicholson J. K. Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. Science. 1986 Jan 24;231(4736):382–385. doi: 10.1126/science.3001934. [DOI] [PubMed] [Google Scholar]
  20. McKeating J. A., Cordell J., Dean C. J., Balfe P. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120. Virology. 1992 Dec;191(2):732–742. doi: 10.1016/0042-6822(92)90249-o. [DOI] [PubMed] [Google Scholar]
  21. Moore J. P., Ho D. D. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J Virol. 1993 Feb;67(2):863–875. doi: 10.1128/jvi.67.2.863-875.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Posner M. R., Cavacini L. A., Emes C. L., Power J., Byrn R. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J Acquir Immune Defic Syndr. 1993 Jan;6(1):7–14. [PubMed] [Google Scholar]
  23. Potts B. J., Field K. G., Wu Y., Posner M., Cavacini L., White-Scharf M. Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies. Virology. 1993 Nov;197(1):415–419. doi: 10.1006/viro.1993.1604. [DOI] [PubMed] [Google Scholar]
  24. Reimann K. A., Burkly L. C., Burrus B., Waite B. C., Lord C. I., Letvin N. L. In vivo administration to rhesus monkeys of a CD4-specific monoclonal antibody capable of blocking AIDS virus replication. AIDS Res Hum Retroviruses. 1993 Mar;9(3):199–207. doi: 10.1089/aid.1993.9.199. [DOI] [PubMed] [Google Scholar]
  25. Thali M., Furman C., Wahren B., Posner M., Ho D. D., Robinson J., Sodroski J. Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein. J Acquir Immune Defic Syndr. 1992;5(6):591–599. [PubMed] [Google Scholar]
  26. Tilley S. A., Honnen W. J., Racho M. E., Chou T. C., Pinter A. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. AIDS Res Hum Retroviruses. 1992 Apr;8(4):461–467. doi: 10.1089/aid.1992.8.461. [DOI] [PubMed] [Google Scholar]
  27. Watanabe M., Boyson J. E., Lord C. I., Letvin N. L. Chimpanzees immunized with recombinant soluble CD4 develop anti-self CD4 antibody responses with anti-human immunodeficiency virus activity. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):5103–5107. doi: 10.1073/pnas.89.11.5103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Watanabe M., Ringler D. J., Fultz P. N., MacKey J. J., Boyson J. E., Levine C. G., Letvin N. L. A chimpanzee-passaged human immunodeficiency virus isolate is cytopathic for chimpanzee cells but does not induce disease. J Virol. 1991 Jun;65(6):3344–3348. doi: 10.1128/jvi.65.6.3344-3348.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES